14.82
0.06 (0.41%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Crescent Biopharma, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CBIO | - | - | - | 2.43 |
| SONN | 33 M | - | - | 2.07 |
| CELC | - | - | - | 83.17 |
| ALGS | - | - | - | 1.41 |
| MNPR | - | - | - | 3.66 |
| REPL | - | - | - | 10.78 |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | 0.2 |
| AI Technical info | NA |
| Technical Oscillators info | 2.0 |
| Technical Moving Averages info | -2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.4% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -1.7 |
| Final Score | 0.06 |
Select this tab to load the latest available analysis.
|
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 22.26% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Nov 2026 | Yahoo Finance |
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee… |
| 02 Nov 2026 | Yahoo Finance |
Crescent Biopharma to Present at November Investor Conferences
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at… |
| 15 Oct 2026 | Yahoo Finance |
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Comb
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001… |
| 05 Oct 2026 | Yahoo Finance |
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026 Initial clinical data expected in the second half of 2027… |
| 03 Sep 2026 | Yahoo Finance |
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. |
| 03 Sep 2026 | Yahoo Finance |
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at… |
| 4Y Average Dividend Yield | 0.14% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 Cash |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 Cash |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.10 |
| 2022 | 1.43 | 1 | 0.47 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |